Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, a...
February 21 2017 - 8:00AM
Spring Bank Pharmaceuticals, Inc., (NASDAQ:SBPH), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of viral infections, cancer, and inflammatory diseases,
today announced two abstracts on
SB 11285, its
most advanced STING (
Stimulator of
INterferon
Genes) agonist product
candidate for the potential treatment of certain cancers, have been
accepted for presentation at the
2017 Keystone Symposia:
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream
Oncology (C7), to be held at the Fairmont Chateau Whistler
in Whistler, British Columbia (Canada) on March 19-23, 2017.
Details of Spring Bank’s poster presentations
are as follows:
Title: A Novel Class of STING
Agonists for Immuno-oncology Date and Time: Monday
March 20, 2017 Poster Number: 1036Session
info: Poster Session 1
Title: Characterization of SB
11285 as a novel STING Agonist for Immuno-oncology Date and
Time: Thursday March 23, 2017 Poster
Number: 4074Session info: Poster
Session 4
About Keystone Symposia Conference
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream
Oncology (C7)The fields of cancer immunology and
immunotherapy continue to make great strides in providing both a
comprehensive understanding of the basic mechanisms underlying
tumor-immune system interactions and applying this knowledge to the
development of effective immune-based cancer therapies. This
Keystone Symposia meeting is organized to highlight recent insights
into the complex roles of immune components and pathways in
controlling or alternatively promoting cancer and to showcase
recent uses of cancer vaccines, checkpoint blocking strategies,
adoptive cell therapies and cellular engineering approaches, either
as mono- or combinatorial therapies, that have resulted in durable,
effective and safe therapeutic responses to an increasing number of
cancer patients. Part of the meeting will also focus on new,
developing technologies that are likely to expand our capacity to
monitor the effects of cancer immunotherapy with a precision,
refinement and at a level that has not been possible in the
past.
About Spring Bank
PharmaceuticalsSpring Bank Pharmaceuticals is a
clinical-stage biopharmaceutical company engaged in the discovery
and development of a novel class of therapeutics using its
proprietary small molecule nucleic acid hybrid (SMNH) chemistry
platform. SMNH compounds are small segments of nucleic acids that
the company designs to selectively target and modulate the activity
of specific proteins implicated in various disease states. The
company is developing its most advanced SMNH product candidate, SB
9200, for the treatment of viral diseases, including hepatitis B
virus (HBV). SB 9200 has been designed to selectively activate
within infected cells the cellular proteins, retinoic
acid-inducible gene 1 (RIG-I) and nucleotide-binding
oligomerization domain-containing protein 2 (NOD2), which have been
implicated in the body’s immune response to viral infections.
Spring Bank believes that SB 9200 may play an important role in
antiviral therapy by modulating the body’s immune response through
its mechanisms of action to fight viral infections such as HBV. The
company is also conducting preclinical studies on its most advanced
STING agonist candidate, SB 11285. For more information, please
visit www.springbankpharm.com.
Contact:
Jonathan Freve
Chief Financial Officer
Spring Bank Pharmaceuticals
(508) 473-5993
jfreve@springbankpharm.com
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Sep 2023 to Sep 2024